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ABSTRACT
Background. Autosomal dominant polycystic kidney disease
(ADPKD) is the most common monogenic inherited kidney
disease, affecting an estimated 600 000 individuals in Europe.
The disease is characterized by age-dependent development of
a multiple cysts in the kidneys, ultimately leading to end-stage
renal failure and the need of renal replacement therapy in the
majority of patients, typically by the ﬁfth or sixth decade of
life. The variable disease course, even within the same family,
remains largely unexplained. Similarly, assessing disease
severity and prognosis in an individual with ADPKD remains
difﬁcult. Epidemiological studies are limited due to the frag-
mentation of ADPKD research in Europe.
Methods. The EuroCYST initiative aims: (i) to harmonize and
develop common standards for ADPKD research by starting a
collaborative effort to build a network of ADPKD reference
centres across Europe and (ii) to establish a multicentric obser-
vational cohort of ADPKD patients. This cohort will be used
to study factors inﬂuencing the rate of disease progression,
disease modiﬁers, disease stage-speciﬁc morbidity and mor-
tality, health economic issues and to identify predictive disease
progression markers. Overall, 1100 patients will be enrolled in
14 study sites across Europe. Patients will be prospectively
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followed for at least 3 years. Eligible patients will not have par-
ticipated in a pharmaceutical clinical trial 1 year before enrol-
ment, have clinically proven ADPKD, an estimated glomerular
ﬁltration rate (eGFR) of 30 mL/min/1.73 m2 and above, and be
able to provide written informed consent. The baseline visit
will include a physical examination and collection of blood,
urine and DNA for biomarker and genetic studies. In addition,
all participants will be asked to complete questionnaires detail-
ing self-reported health status, quality of life, socioeconomic
status, health-care use and reproductive planning. All subjects
will undergo annual follow-up. A magnetic resonance imaging
(MRI) scan will be carried out at baseline, and patients are en-
couraged to undergo a second MRI at 3-year follow-up for
qualitative and quantitative kidney and liver assessments.
Conclusions. The ADPKD reference centre network across
Europe and the observational cohort study will enable Euro-
pean ADPKD researchers to gain insights into the natural
history, heterogeneity and associated complications of the
disease as well as how it affects the lives of patients across
Europe.
Keywords: ADPKD, biomarker, cohort, EuroCYST, risk
factors
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is
one of the most common monogenic genetic diseases, affect-
ing ∼1 in 1000 live births, that is ∼600 000 individuals in
Europe [1]. The disease is characterized by the development of
multiple cysts in both kidneys and by potentially serious com-
plications [2]. Disease manifestations impairing quality of life
include hypertension, chronic pain, intracranial aneurysms,
abdominal hernias, haematuria, urinary tract infection and
kidney stones. Kidney function is often preserved up to the age
of 40, but subsequently glomerular ﬁltration rate (GFR) de-
creases and often leads to end-stage renal disease (ESRD) [3].
However, there is wide variability between subjects in disease
course, even within families that share the same mutation,
with some patients never reaching ESRD.
ADPKD represents a major burden for public health in the
EU, estimated at €1.6 billion annually for direct medical costs
related to renal replacement therapy [4]. This ﬁgure is an
underestimate of the true economic burden, because it does
not take into account costs related to co-morbidities that fre-
quently occur in patients with impaired kidney function and
the loss of income generation that is often observed in subjects
with later stage kidney disease. Research on prevention of
ADPKD-related complications could therefore offer a tremen-
dous return on investment.
At present, there are no approved disease-modifying treat-
ments available for ADPKD. Intensive basic research during
the last three decades has contributed to a clearer understand-
ing of the basic pathophysiological processes that lead to renal
cyst formation in subjects affected by ADPKD with deﬁnition
of novel therapeutic targets [5, 6]. In animal studies, some of
the treatments directed at these targets, such as mammalian
target of rapamycin (mTOR) inhibitors, somatostatin ana-
logues and vasopressin V2-receptor antagonists (V2RA), have
shown promising results [7–9]. The clinical trials testing
mTOR inhibitors showed no clear impact on disease pro-
gression [10–12]. However, recent results from the TEMPO
3:4 and ALADIN trials with the V2RA tolvaptan and the
somatostatin analogue octreotide have shown an effect on the
rates of kidney growth and kidney function decline, although
long-term treatment safety needs to be addressed [13, 14]. If
these therapies become available for clinical use, the pivotal
question will be which patients to select for treatment. One
can hypothesize that ADPKD patients with rapid disease pro-
gression would beneﬁt most and that treatment should be
started at an early stage of disease, when the kidneys are more
likely to respond to an intervention. Since ADPKD is charac-
terized by a long period of stable kidney function, due to com-
pensatory ﬁltration of unaffected nephrons, kidney function
does not accurately reﬂect disease severity nor prognosis [15].
Genotype (PKD1 as opposed to PKD2 mutation), male gender
and young age at onset of hypertension among others associ-
ate with faster disease progression in ADPKD [16, 17].
However, the predictive value of these variables is limited and
untested in large prospective cohorts. The identiﬁcation of
surrogate markers to assess disease severity and risk of pro-
gression and to monitor the effect of interventions on the
course of disease remains an important goal and is an unmet
medical need. Results of smaller observational studies in
ADPKD cohorts, such as CRISP and SUISSE ADPKD, suggest
that changes in total kidney volume (TKV) are a predictor of
subsequent loss of kidney function [18]. Magnetic resonance
imaging (MRI) has a greater sensitivity for the detection of
small cysts and allows to measure kidney and liver volume
more precisely compared with ultrasound. It has been shown
that MRI can already reliably detect changes in TKV that
occur during 6 months of follow-up [19]. However, the two in-
terventional trials with mTOR inhibitors (refs [10] and [11])
did not observe a correlation between total renal volume and
disease progression (as measured by renal function) question-
ing whether TKV is a suitable surrogate marker for disease
progression. In addition, this imaging technique is not routine
clinical practice for ADPKD subjects in all European countries.
Thus, there is a need to discover clinical factors or new bio-
markers that predict the rate of disease progression.
Building a large, well-characterized cohort of ADPKD
subjects who are followed in a longitudinal observational
cohort study has the potential to identify progression fac-
tors and biomarkers, and to assess disease stage-speciﬁc
mortality, morbidity and health-care costs. This knowledge
should translate into new diagnostic and therapeutic modal-
ities. This approach requires a coordinated multinational
action within a network of ADPKD reference centres. The
EuroCYST initiative aims to build such a network and to es-
tablish a large-scale pan-European ADPKD cohort serving as
a versatile and powerful clinical research platform. Since
EuroCYST is an academic initiative and not industry driven,
free access to information and pseudo-anonymized bio-
material is ensured, as approved by a research oversight
committee.
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METHODS
Objectives
The primary objectives of the EuroCYST initiative are to:
(i) Build a network of ADPKD reference centres across
Europe to provide a translational research platform
that will enable EU researchers to study the pathogen-
esis, progression factors, morbidity, co-morbidity and
health economic issues in ADPKD patients over a wide
range of kidney function and kidney volume.
(ii) Harmonize and develop common standards for
ADPKD-related research by a collaborative effort to es-
tablish a pan-European ADPKD cohort.
(iii) Harmonize and develop a common ADPKD biobank
that includes standardized, quality-controlled bioma-
terials for translational research.
(iv) Create a scaffold to facilitate the integration of current
and upcoming technologies to ADPKD practice.
(v) Develop evidence-based best practice and need assess-
ments for ADPKD by utilizing the outcomes of the
EuroCYST initiative and by engaging with relevant sta-
keholders, including patient organizations, clinical and
research networks, legislators, policymakers and the
pharmaceutical industry.
(vi) Serve as an impetus to expand ADPKD training pro-
grammes at all levels by establishing collaborative and
educational liaisons as well as provide standard criteria
for effective management protocols in ADPKD.
(vii) Improve awareness of the relevance of ADPKD includ-
ing disease-speciﬁc complications and socioeconomic
consequences of the disease among health-care pro-
fessionals and payers.
EuroCYST strategy and organization
To build a cohort for a longitudinal observational study,
14 centres in 10 countries across Europe (Figure 1) will enrol
1100 adult ADPKD patients until the end of 2015. The study
is funded by a grant of the ERA–EDTA with 1 million Euros.
For optimal utilization of the funding, centres with expertise
in ADPKD and already existing local clinical cohorts have
been co-opted, so that efforts do not need to focus on rec-
ruitment, but can be invested into the establishment of the
cohort infrastructure, uniform data recording and in-depth
analysis of several time and thus resource-consuming as-
pects, such as assisted patient interviews using standardized
questionnaires.
The enrolment phase started in summer 2013; within 1 year,
250 participants should be included. To reach the goal of re-
cruiting 1100 ADPKD patients, each participating ADPKD
centre will enrol at least 50 and up to a maximum of 100
patients within 2 years to ensure a representative distribution
of patients across Europe. In a second step, which is beyond
the current funding period, the cohort could be extended in
F IGURE 1 : Location of participating study sites in the EuroCYST initiative.
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four ways to: (i) prolong the intended duration of follow-up to
longer than 3 years, (ii) increase the number of patients up to
5000 or more through the participation of additional Euro-
pean study centres with a minimum essential dataset, (iii) in-
crease the information density per patient for speciﬁc aspects
(e.g. cardiovascular pathology, imaging and genetics) or
(iv) enrol partners, children and parents of index patients
(three-generation cohort). The participation of additional cen-
tres will be possible if appropriate funding is obtained. Collab-
orations at various levels with other research groups to share
data and biomaterials in order to achieve maximum scientiﬁc
output will be encouraged. To this end, an open and transpar-
ent ancillary study policy has been established as part of the
study protocol (Supplementary data S1).
A Steering Committee has been established and is meeting
at least twice a year. All decisions by the Steering Committee
will be approved on a 75% majority. The establishment of a
Central Study Coordination Team, which meets on a bi-weekly
basis, will ensure rapid and successful project implementation
and progress.
Eligibility of cohort participants
Following a consecutive enrolment approach, all patients
with ADPKD are considered as potentially eligible for the
study at pre-screening and will undergo screening for the
study. Patients aged 18 years and older with an estimated
GFR (eGFR) of 30 mL/min/1.73 m2 and higher [chronic
kidney disease-epidemiology collaboration (CKD-EPI)
formula], having a diagnosis of ADPKD established based on
kidney ultrasound and family history (modiﬁed Ravine
criteria) who have not taken part in a disease-modifying trial
at least 1 year or shorter before enrolment and are able to
provide written informed consent, will be eligible for enrol-
ment into the EuroCYST cohort [20, 21]. Table 1 displays the
inclusion and exclusion criteria. Exclusion criteria include the
likelihood of reaching ESRD within 1 year after enrolment or
signiﬁcant heart disease according to New York Heart Associ-
ation Stage IV (NYHA Stage IV) [22]. A stratiﬁcation strategy
based on subjects’ eGFR will avoid a selection bias. Thus, 40 to
60% of included patients in each study center need to have an
eGFR of 60 mL/min/1.73 m2 and more.
Study design
Patients who meet the inclusion criteria will be invited to
participate. All potential participants will receive detailed
information about the study both verbally and in writing.
Local ethical committees will approve the study, and the pro-
tocol has to fulﬁl the local regulatory requirements and com-
plies with Good Clinical Practice (GCP) Guidelines.
The study design is shown in Figure 2. At baseline, a de-
tailed medical and ADPKD-speciﬁc assessment will be per-
formed. Family history/pedigree information will be collected,
as well as information on medical resource use (health-care
visits, hospital admission, procedures and medication), pro-
ductivity (employment and absenteeism), information culture
within families and reproductive planning. The economic and
social position, based on income, education and occupation,
will be assessed. Quality of life will be measured by asking
patients to complete the KDQOL-SF 1.2™ questionnaire, which
includes questions relating to patients’ general health, kidney
disease and about the effect of the disease on activities of daily
living. The protocol will also require a physical examination.
Follow-up visits will be conducted on an annual basis until
the end of study, withdrawal, ESRD or death. Follow-up visits
will include physical examination, laboratory analyses and
completing the aforementioned ADPKD-related question-
naires. Participating patients will be treated according to
current standards of care in routine clinical practice within
each country.
Magnetic resonance imaging
MRI will be used to measure the different magnitudes and
volume parameters of kidney and liver. MRI will be performed
at the baseline visit and is recommended at 3-year follow-up.
To obtain high-quality renal and hepatic imaging and main-
tain consistency between the centres participating in the trial,
a standardized protocol has been developed. The MRI acqui-
sition protocol includes T2 single-shot fast/turbo spin-echo
images with fat-saturation, FISP or FIESTA 3D spoiled gradi-
ent echo and T1-3D spoiled gradient echo. Images will be
sent using the Picture Archiving and Communication System
Table 1. Inclusion and exclusion criteria for the EuroCYST observational
cohort study
Inclusion criteria
Age ≥18
eGFR ≥30 mL/min/1.73 m2 (CKD-EPI formula)
Clinical diagnosis of ADPKD based on kidney imaging and family
history (modiﬁed Ravine criteria)
Patient provided written informed consent
Exclusion criteria
Receiving chronic renal replacement therapy before enrolment
(dialysis and allograft) or anticipated to receive such therapy within
12 months after enrolment
Participation in a clinical trial aiming to modify disease outcome
1 year or less before enrolment in the EuroCYST study
NYHA stage IV
ADPKD, autosomal dominant polycystic kidney disease; eGFR, estimated glomerular
ﬁltration rate; NYHA, New York Heart Association. F IGURE 2 : Study design.
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(PACS) to the centres in Zurich and Bergamo, where a read
out by trained personnel will be performed. Read out of the
scans includes whole kidney and cyst volume, length, depth,
width of the kidney, numbers of cysts and also liver and liver
cyst volume, using the workstation GE Advantage and the pro-
gramme volume viewer.
Collection and storage of biomaterials
The collection of material for biobanking will be conducted
at the baseline visit. A standard operating procedure (SOP)
harmonizes the procedure for sampling, pre-processing and
storage of biobanking material within the EuroCYST initiative.
Serum, plasma andwhole blood collected onEDTAand spotted,
and a 24-h urine sample will be collected, processed and ali-
quoted. They will be shipped in batches to a central biobank
storage facility where an automated −80°C sample library
management system is in place to handle the de-identiﬁed 2D
bar-coded sample vials. The whole blood tubes will be shipped
to a central, certiﬁed genetic laboratory for DNA extraction
and storage. The database will be kept separately with a secure
method to link clinical information to biological samples.
Data management and protection
Data collection and data management will be conducted
using the web-based data management system SecuTrial®, with
a data capture, which has been approved by the US Food and
Drug Administration (FDA) and that fulﬁls the requirements
of the International Conference on Harmonization Good
Clinical Practice (ICH GCP) and Good Clinical Data Manage-
ment Practices (GCDMP). All electronic case report forms
(eCRF) have been implemented into this system. Figure 3
shows the different subject areas of the data bank that are re-
ﬂected in the eCRF. Data will be stored for at least 10 years
after study termination and a daily back up will be performed.
The study data are saved on a separate server at the University
Hospital Zurich, where the clinical trial centre, provider of the
data management system, is located. Server access is controlled
physically and electronically. Each patient will be pseudo-
anonymized in a reversible manner, and all data introduced
into the data management system are coded. Subject identiﬁ-
cation will only be possible at the local study site. Access to the
system will be role speciﬁc and will only be possible with a
unique user-ID and password. High data quality will be
ensured by performing regular monitoring and reporting of
entered data by the coordination centre in Zurich. All study
site data entered in the eCRF will be checked for completeness
and plausibility according to predeﬁned rules to draw attention
to missing data or errors. Certiﬁed personnel will monitor the
participating centre annually. All patients’ written informed
consent forms and all study ﬁles will be checked for complete-
ness, and remain at the individual sites. In 10% of locally en-
rolled patients, the source ﬁles and eCRFs will be checked for
accuracy. In addition, frequent communications and annual
meetings of reference centre principal investigators will ensure
study compliance. The centre’s individual results of the study
shall be owned by the centre. Each centre will provide copies
of all results, including but not limited to case report forms, to
the study coordination centre in Zurich. Owner of the overall
data of the initiative is the EuroCYST Steering Committee.
Statistical considerations
Formal sample size estimation has not been performed for
this study. While chronic kidney disease cohorts currently aim
to enrol at least 3000 and up to 5000 patients (CRIC, CKD
JAC and GCKD) to identify valid associations in subgroups,
the common genetic origin in APDKD allows important
F IGURE 3 : Content of the databank.
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conclusions to be drawn using a smaller sample size [23–25].
On the other hand, groups of several hundred patients en-
rolled in recent randomized controlled trials as well as already
existing ADPKD cohorts have displayed large variability in the
disease progression rate as assessed by the change in eGFR
rate and TKV despite restrictive inclusion and exclusion cri-
teria. Therefore, a larger sample size is required to account for
the broader range in age and renal function in our cohort. A
mixed-effects regression model will be used as the modelling
framework, with a random effect for each patient (this allows
correlation between repeated eGFR or TKV measurements in
the same patient) and with ﬁxed effects for time with a spline
structure to model change in eGFR and TKV.
Study outcomes
The primary outcome measure of the study will be disease
progression, assessed as change in eGFR (CKD-EPI) and
change in TKV. Secondary outcome measure will be: ﬁrst,
onset and severity of ADPKD-related clinical outcomes, such
as hypertension, albuminuria, renal urine concentrating
ability, haematuria, renal pain, cyst infection and nephrolithia-
sis; secondly, self-reported health status, quality of life and
pain; and thirdly, health-related resource use and ADPKD-
related health burden.
Enrolment start
The study started enrolling patients in July 2013 and will
run for 36 months.
CONCLUSION
The fragmentation of cohorts of ADPKD patients in Europe
has been an obstacle to a better understanding of disease
characteristics. Individual efforts in different countries often
have little inter-changeability and it can be almost impossible
to connect detailed clinical information held in one database
with genetic information or biomaterial sample availability
held in other databases. Our increasing knowledge of the basic
biology of ADPKD has led to the identiﬁcation of multiple
novel targets in pre-clinical studies, which will need to be
tested in patients. Positive results from recent clinical trials
also now compel nephrologists to ﬁnd new ways of risk stratiﬁ-
cation to identify patients at higher risk of disease progression
and who may beneﬁt most from early intervention. So far,
limited data are available addressing patients’ quality of life,
disease-related health burden, health-care resource use and re-
productive planning. Currently, available data regarding quality
of life for ADPKD patients are limited and often only appli-
cable to those on dialysis or transplanted patients [26–29].
These issues motivated the EuroCYST initiative, which
aims to build an ADPKD reference centre network in Europe
in order to establish a large pan-European observational cohort
that will serve as a scaffold and platform enabling researchers
to study the pathogenesis, progression factors, mortality, co-
morbidity as well as health economic issues relevant to ADPKD
as a major cause of kidney disease. Although there is an inter-
est of the pharmaceutical industry to establish ADPKD
databases, an independent academic network with a transpar-
ent open access policy remains essential. The recent establish-
ment of the ERA–EDTAWorking Group on Inherited Kidney
Disorders demonstrates the interest and need for a consoli-
dated pan-European approach in the ﬁeld of inherited kidney
diseases at large [30].
The establishment of such a cohort has the potential to
strengthen European ADPKD investigators by harmonizing
and standardizing research efforts and will guarantee that
current and upcoming technologies to study chronic kidney
disease can be applied to ADPKD patients across Europe.
Affected patients and their relatives will beneﬁt from the
scientiﬁc-medical innovations by improved prevention and
awareness, treatment of disease-speciﬁc complications and de-
velopment of new diagnostic and therapeutic modalities.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.
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